NorthStrive and Yuva use AI to find cardiac, obesity drug leads

NorthStrive Biosciences expanded its AI program with Yuva Biosciences, aiming to advance four AI-discovered small-molecule compounds. The six-month program targets lead nomination for cardiac disease and obesity therapeutics, building on existing positive Phase III results.